Clinical Trial Update: Long-term Immunogenicity After Receipt of JE Vaccine and Antibody Response and Safety to a Booster Dose [Phase 4]

View source ↗

Summary

Phase 4 trial assessing long-term immunogenicity, antibody response, and safety after a booster dose of JE vaccine in Japanese encephalitis virus exposure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Japanese Encephalitis

Drugs mentioned

• JE vaccine

Snippet

Sponsor: PATH | Conditions: Encephalitis, Japanese | Phase 4 | Status: COMPLETED | Results posted: 2020-10-19